28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Zinc deficiency represents an independent, modifiable risk factor for new-onset dementia with a clear dose-response relationship. 5 key findings →
Design: cohort study Participants: 34,249 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In addition to outperforming existing plasma biomarkers, the dSST predicted mid-life dementia risk over a 20-year follow-up across two independent cohorts with different ethnic backgrounds (areas under the curve [AUCs]: dSST 0.68-0.70, dSST+age 0.75-0.81). 4 key findings →
Design: longitudinal study Participants: 11,277 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
BackgroundAccurate and accessible risk assessment tools are essential for effective dementia management. 3 key findings →
Design: longitudinal study Participants: 27,768 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We identified a total of 1,686,759 patients with incident dementia (mean (SD) age, 82.15 (6.90) years; 61.70% female) and 3,373,518 matched controls (mean (SD) age, 82.15 (6.90) years; 61.70% female). 5 key findings →
Design: cohort study Participants: 1,686,759 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among all participants, 247 (11.7%) had IADL limitations at baseline, and 151 (7.1%) developed dementia during follow-up. 5 key findings →
Design: longitudinal study Participants: 2,118 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
CogDrisk-ML outperformed CAIDE in the UK Biobank and Whitehall II cohorts; however, it provided similar C statistics in the ARIC dataset. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The telmisartan group had the lowest risk of all dementias (telmisartan vs NT-ARB: hazard ratio [HR]: 0.78; 95% confidence interval [CI]: 0.60 to 1.01; telmisartan vs angiotensin-converting enzyme inhibitor: HR: 0.67; 95% CI: 0.48 to 0.94). 5 key findings →
Design: cohort study Participants: 39,665 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In a longitudinal study of senile dementia and healthy aging, the occurrence of serious falls was examined in participants with senile dementia of the Alzheimer's type (SDAT) (n = 44) and in cognitively healthy elderly control participants (n = 56) over a 4-year period. 4 key findings →
Design: longitudinal study Participants: 44 Evidence: moderate
Full summary, score breakdown and related studies → Original source
APs appear to increase the risk of hip fracture among older adults with dementia residing in an NH. 3 key findings →
Design: case-control study Participants: 586 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Older people with diabetes receiving metformin have slower cognitive decline and lower dementia risk. 5 key findings →
Participants: 1,037 Evidence: high
Full summary, score breakdown and related studies → Original source
Serum Abeta40/42 ratio was significantly higher in MDD patients than in controls, and this difference was seen for both elderly and young subjects. 5 key findings →
Design: cohort study Participants: 60 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We identified a series of transmembrane proteins, proteins associated with or anchored to the plasma membrane, and proteins involved in or connected to synaptic vesicle transport to be associated with CSF biomarkers of amyloid and tau pathology in AD. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The importance of digital data in its native format, near real-time data access, passive participant engagement, and availability of technologies across OS has been supported by the pattern of participant technology use and adherence across cohorts. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Genetic risk for AD does not modify the association between hypertension and dementia. 4 key findings →
Design: cohort Participants: 11,597 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our findings highlight the importance of personalized risk assessments and the development of tailored interventions based on genetic background to prevent dementia more effectively. 5 key findings →
Design: cohort Participants: 182,473 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Antihypertensive treatment significantly improved cognitive function scores (SMD, 0.06; 95% CI, 0.03-0.09; P Conclusions and implications Antihypertensive therapy significantly improves cognitive function with moderate certainty evidence, supporting its use for cognitive protection in older adults with hypertension. 2 key findings →
Design: meta-analysis Participants: 16,823 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Smoking and education, which have opposing risk effects on AD and PD, are not risk factors for DLB; however, depression and low caffeine intake, both risk factors for AD and PD, increase risk of DLB more strongly than in either. 2 key findings →
Participants: 147 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Although most falls do not result in injury, the fact that residents with dementia fall more often than their counterparts without dementia leaves them with a higher overall risk of sustaining injurious falls over time. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Of 502 535 participants in UK Biobank, 143 215 met the inclusion criteria and were included in our analyses. 68 500 (47·8%) of the participants were pre-frail and 5565 (3·9%) were frail. 4 key findings →
Participants: 535 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Recent findings suggest that a rich social network may decrease the risk of developing dementia. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In our study, TSH was related neither to risk of AD nor with early MRI markers thereof, arguing against an important role of thyroid function in the development of AD. 4 key findings →
Design: cohort study Participants: 1,025 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study robustly characterized the prevalence of sleep complaints in large samples of the elderly in LAMICs and identified potential risk factors that may be specific to these populations. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The number of older adults with dementia in the US and globally is projected to increase as a result of population aging and growth. 5 key findings →
Design: cross-sectional Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Inflammatory responses are associated with cardiovascular disease and may be associated with dementing disease. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The authors explored the possibility that estrogen loss associated with menopause may contribute to the development of Alzheimer's disease by using a case-control study nested within a prospective cohort study. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
10 of the 1,143 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →